Ebstein Anomaly

• Embryologic Defect: Failure of normal delamination of the tricuspid valve leaflets from the right ventricular myocardium during weeks 4-7 of gestation. The septal leaflet and posterior leaflet fail to separate adequately, becoming adherent to the ventricular wall rather than inserting at the annulus. This results in apical displacement of the functional annulus (typically >8 mm/m² body surface area is diagnostic), effectively enlarging the right atrium and reducing the functional right ventricular chamber.

• Hemodynamic Consequences: Severe tricuspid regurgitation develops due to leaflet dysplasia and inadequate coaptation, leading to systolic backflow into the right atrium and subsequent right atrial enlargement and dilation. This chronic volume overload increases right atrial pressure, promoting right-to-left shunting through patent foramen ovale or atrial septal defect, causing cyanosis (degree proportional to shunt magnitude). Right ventricular dysfunction occurs from both the volume load of regurgitation and intrinsic myocardial abnormality in the "atrialized" right ventricle (the portion between the displaced valve and the true annulus that becomes thin-walled and functionless).

• Arrhythmia Substrate: The enlarged right atrium provides an enormous substrate for macro-reentrant atrial arrhythmias, particularly atrial fibrillation and atrial flutter. The abnormal embryologic development predisposes to accessory atrioventricular pathways in 5-10% of patients, with the most common being pathways inserting near the tricuspid annulus, creating additional risk for atrioventricular reentrant tachycardia (AVNRT). These arrhythmias can precipitate acute hemodynamic deterioration due to loss of atrioventricular synchrony and rapid ventricular rates in the setting of impaired right ventricular function.

• Sporadic Mutations (most common, ~80% of cases): De novo mutations in genes regulating cardiac development, including mutations in NKX2.5, GATA4, GATA6, and genes encoding chromatin remodeling complexes. No clear genetic inheritance pattern in majority of sporadic cases, though familial clustering has been observed with autosomal dominant inheritance in rare families.

• Maternal Lithium Exposure (well-established teratogen): First-trimester exposure to lithium carbonate for maternal bipolar disorder increases incidence 40-fold compared to general population. The critical period is during cardiac organogenesis (weeks 4-7); lithium inhibits inositol metabolism and glycogen synthase kinase-3β, disrupting normal embryonic development. Notably, this association is the most common environmental cause of Ebstein anomaly, though absolute incidence remains low even with exposure.

• Associated Genetic Syndromes: Part of spectrum seen in Down syndrome (Trisomy 21), DiGeorge syndrome (22q11 deletion), and other chromosomal abnormalities; autosomal dominant inheritance reported in familial cases with variable penetrance and expressivity.

• Neonatal/Infantile Presentation (Severe Forms):
• Cyanosis present immediately after birth or within first hours of life, typically mild to moderate (SpO₂ 75-85%) and potentially worsening with age as pulmonary vascular resistance drops
• Severe respiratory distress and poor feeding due to right heart failure and pulmonary edema
• Hepatomegaly from systemic venous congestion
• Failure to thrive and developmental delay

• Childhood/Adolescent Presentation (Moderate-to-Mild Forms):
• Dyspnea on exertion and exercise intolerance due to inadequate increase in cardiac output during activity
• Palpitations from atrial arrhythmias (atrial fibrillation in ~10% by adulthood), which may be the presenting complaint
• Mild cyanosis only with activity in some patients; "clubbing" of fingers in long-standing cyanosis
• Growth retardation in some children with moderate-to-severe disease

• Adult Presentation (Often Mild/Asymptomatic):
• Many patients reach adulthood asymptomatic or with incidental finding on imaging performed for other reasons
• Presentation with new-onset atrial fibrillation with rapid ventricular response (can cause acute decompensation)
• Progressive dyspnea, orthopnea, and peripheral edema from right heart failure
• Sudden cardiac death from arrhythmia in patients with accessory pathway

• Physical Examination Findings:
• Loud S2 split with fixed splitting (due to right ventricular volume overload and prolonged right ventricular ejection time)
• Single loud S2 in severe cases with minimal pulmonary blood flow
• "Sail sign" on auscultation: prominent, sail-like systolic murmur of tricuspid regurgitation best heard at left lower sternal border
• Prominent diastolic filling sound (S3 or S4): multiple heart sounds creating characteristic "quadruple rhythm" or "quintuple rhythm" (S1-S2-S3-S4 sounds)
• Hepatomegaly with prominent systolic hepatic pulsation (reflecting severe tricuspid regurgitation) and elevated jugular venous pressure (often very elevated)
• Cyanosis and clubbing in moderate-to-severe disease
• Edema and ascites in right heart failure

• Electrocardiography (Often First Abnormality Detected):
• Tall, peaked P waves ("P pulmonale") reflecting right atrial enlargement—often the most characteristic finding
• Right axis deviation (QRS axis >90°) due to rightward orientation from massive right atrial enlargement
• Prolonged PR interval and first-degree atrioventricular block (present in ~50% of patients)
• Atrial arrhythmias: paroxysmal or persistent atrial fibrillation/flutter, often with rapid ventricular response
• Pre-excitation pattern (short PR interval with delta wave) in 5-10% of patients with concurrent accessory pathway (Wolff-Parkinson-White syndrome)
• Low QRS voltage in some cases despite cardiomegaly (paradoxical finding termed "low voltage-big heart" syndrome)

• Chest X-ray:
• Marked cardiomegaly with dramatically enlarged cardiac silhouette (cardiothoracic ratio often >0.6-0.8), predominantly from massive right atrial enlargement
• "Narrow waist" appearance: characteristic narrowing at level of pulmonary artery due to the hypoplastic outflow tract
• Decreased pulmonary vascular markings (oligemic lung fields) reflecting reduced pulmonary blood flow due to right-to-left shunting through ASD/PFO
• Pulmonary edema in decompensated states

• Transthoracic Echocardiography (Gold Standard for Diagnosis):
• Apical displacement of septal and posterior tricuspid valve leaflets ≥8 mm/m² body surface area (measured from the lateral tricuspid annulus to the attachment point of septal leaflet in apical 4-chamber view)
• "Sail sign": septal leaflet protrudes into right ventricular outflow tract in parasternal short-axis view, resembling a sail
• Severely dilated right atrium with or without rightward bowing of interatrial septum
• Thin-walled, hypoplastic right ventricle with reduced contractility
• Severe tricuspid regurgitation on color Doppler with prominent systolic flow reversal in hepatic veins
• Increased RV/LV diastolic dimension ratio
• Degree of left ventricular dys function: secondary left ventricular changes from septal flattening and paradoxical motion
• Atrial septal defect or patent foramen ovale (present in majority; can assess shunting direction)
• Estimate of pulmonary artery systolic pressure from tricuspid regurgitation jet
• Tissue Doppler may reveal reduced RV free wall longitudinal strain and early diastolic dysfunction

• Cardiac Magnetic Resonance Imaging:
• Precise quantification of tricuspid regurgitation volume and regurgitant fraction
• Detailed anatomic assessment of valve morphology and displacement
• Right ventricular volume and ejection fraction calculation (important for prognostic assessment and surgical planning)
• Identification of myocardial fibrosis in the atrialized RV or right atrial wall (associated with arrhythmia substrate)
• Assessment of left ventricular function and geometry

• Cardiac Catheterization:
• No longer required for diagnosis but indicated for hemodynamic assessment in selected cases (assessment of pulmonary vascular resistance, calculation of shunt ratio)
• Electrophysiology study: indicated when considering ablation or in patients with symptomatic pre-excitation
• Reveals elevated right atrial pressure (prominent X descent due to restrictive physiology) and prominent Y descent (rapid early diastolic RV filling)
• Increased a wave in right atrial tracing reflecting reduced compliance

• Diagnostic Criteria (Diagnostic and Pathological Institute Criteria):
• Marked displacement of septal tricuspid leaflet (≥20 mm in adults, ≥8 mm/m² BSA)
• Redundant, fenestrated anterior leaflet
• Atrialization of right ventricle
• Right atrial enlargement
• Right-to-left shunt at atrial level

• Asymptomatic Patients Without Hemodynamic Compromise:
• Observation and serial echocardiography (every 1-2 years) with clinical reassessment for development of symptoms
• Avoid strenuous exercise and competitive sports to minimize risk of sudden cardiac death from arrhythmias
• Counseling regarding pregnancy risks (increased peripartum complications and arrhythmia risk)
• Antibiotic prophylaxis for endocarditis not routinely recommended (unless concurrent cyanotic heart disease)

• Symptomatic Medical Management (First-Line):
• Diuretics (furosemide or other loop diuretics): mainstay of therapy to reduce right ventricular volume and right atrial pressure, improving symptoms of heart failure
• Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs): improve right ventricular afterload and promote remodeling in those with borderline RV function or concurrent left ventricular involvement; evidence more limited than in left-sided heart failure
• Beta-blockers (e.g., metoprolol, atenolol): particularly valuable for rate control in atrial fibrillation and arrhythmia prevention; may improve exercise tolerance
• Antiarrhythmic medications:
• Flecainide or sotalol for atrial arrhythmia suppression in patients without accessory pathway (Class IC antiarrhythmics relatively contraindicated in patients with WPW due to risk of rapidly conducting atrial fibrillation)
• In patients with WPW and atrial fibrillation, avoid AV node-blocking agents (digoxin, beta-blockers, calcium channel blockers) as they preferentially block AV node and may accelerate conduction through accessory pathway, potentially causing ventricular fibrillation; use Class IA or IC antiarrhythmics instead

• Cyanotic Patients:
• Prostaglandin E1 (PGE1) infusion: in neonates to maintain patent ductus arteriosus and preserve pulmonary blood flow, critical bridge to definitive therapy
• Supplemental oxygen and avoidance of dehydration (hyperviscosity worsens cyanosis)
• Management of polycythemia if hematocrit >55-60% with phlebotomy and volume replacement to prevent thrombotic complications

• Definitive Surgical Treatment (Indications):
• Symptomatic patients with severe hemodynamic compromise (NYHA Class III-IV despite medical therapy)
• Cyanotic patients (SpO₂ <80% at rest or with activity)
• Severe right ventricular dysfunction (ejection fraction <40% or severely dilated RV with symptoms)
• Progressive exercise intolerance despite medical optimization
• Recurrent symptomatic arrhythmias despite medical therapy and/or ablation

Surgical Options

• Carpentier procedure (valve repair): most common approach with excellent outcomes. Involves plication of atrialized right ventricle, repositioning and remodeling of valve leaflets with annuloplasty, and closure of ASD/PFO. Preferred in most centers for symptomatic patients due to lower operative mortality and superior long-term valve function compared to replacement. Success rates ~80-90% for symptom improvement.
• Valve replacement: reserved for patients with leaflet tissue inadequate for repair or recurrent failure of repair
• 1.5-ventricle repair or Fontan procedure: considered in patients with severely hypoplastic right ventricle or markedly reduced RV function unsuitable for biventricular repair; increasingly performed with excellent outcomes in select patients

• Arrhythmia Management:
• Catheter ablation: first-line definitive therapy for accessory pathway-mediated tachycardia (WPW) with excellent success rates (>90%) and lower recurrence risk than antiarrhythmic drugs. Emergency electrophysiology study and ablation indicated in patients presenting with hemodynamically unstable arrhythmias.
• Atrial fibrillation/flutter ablation: increasingly performed with success rates of 60-75% for maintenance of sinus rhythm; may be combined with structural surgery
• Implantable cardioverter-defibrillator (ICD): considered in patients with family history of sudden cardiac death, recurrent syncope, or severe RV dysfunction (ejection fraction <30%)

• Monitoring and Risk Stratification:
• Serial echocardiography: every 1-2 years to assess RV size, function, and tricuspid regurgitation progression
• Holter monitoring: periodic assessment for arrhythmias in asymptomatic or minimally symptomatic patients
• Exercise stress testing: carefully performed in select patients to assess symptomatic status and risk stratification, though competitive sports generally contraindicated
• Pregnancy counseling: increased risk of peripartum complications, arrhythmias, and fetal complications; requires cardiology co-management

• Atrial Arrhythmias (Most Common Complication):
• Atrial fibrillation develops in 10-15% of adult patients and often presents with hemodynamic instability due to loss of atrial "kick" and rapid ventricular rates
• Atrial flutter and macro-reentrant atrial tachycardia due to enlarged right atrium providing substrate
• Increased stroke risk from atrial fibrillation with need for anticoagulation (warfarin or novel anticoagul

• The one-line definition: failure of leaflet delamination → apical displacement of the septal and posterior tricuspid leaflets, an atrialized right ventricle, a small functional RV, and severe tricuspid regurgitation. If a stem gives "displaced tricuspid valve + huge right atrium," the answer is Ebstein.

• The association examiners test: first-trimester lithium exposure. The risk is real but the absolute risk is low, and most cases are sporadic — a stem pairing maternal bipolar disorder with neonatal cyanosis is pointing at Ebstein.

• The arrhythmia link: right-sided accessory pathways → delta wave, short PR, and atrioventricular reentrant tachycardia (AVRT), plus atrial flutter/fibrillation from the dilated atrium. Ebstein is the classic structural disease paired with WPW.

• Pre-excited atrial fibrillation is the trap: irregular, wide, rapidly conducted QRS complexes. Per the ACC/AHA/HRS supraventricular tachycardia guideline, avoid AV nodal blockers (adenosine, diltiazem, beta blockers, digoxin) — they favor accessory-pathway conduction and can precipitate VF. Use procainamide or, if unstable, synchronized cardioversion; definitive therapy is catheter ablation.

• Best next step in any suspected case: transthoracic echocardiography — diagnostic and the modality that quantifies displacement, RV function, and shunt direction. ECG and CXR are supportive, not confirmatory.

• Classic imaging/exam buzzwords: box-shaped or "wall-to-wall" cardiomegaly with a narrow waist and oligemic lungs; tall P pulmonale ("Himalayan") P waves with RBBB; a quadruple/quintuple rhythm with a widely split S2 and a holosystolic murmur that increases with inspiration (Carvallo sign).

• Cyanosis is shunt-mediated, through a PFO/ASD, so it does not correct with supplemental oxygen; expect paradoxical embolism, stroke, and brain abscess risk. A cyanotic neonate dependent on ductal pulmonary flow needs prostaglandin E1.

• Common distractor: tricuspid atresia, which also causes cyanosis with a small RV but classically shows left axis deviation and RV hypoplasia without leaflet displacement.

• Per AHA endocarditis-prophylaxis criteria, prophylaxis applies to unrepaired cyanotic disease, not to acyanotic Ebstein.